Typ-2-Diabetes im Alter

ZUSAMMENFASSUNG

Im Alter wird die Prognose des Typ-2-Diabetes nicht so sehr durch die Qualität der Stoffwechseleinstellung bestimmt, sondern vielmehr durch die verbleibende Lebenszeit und vor allem durch die Funktionalität des Patienten. Wichtig ist es daher, Komorbiditäten zu berücksichtigen und kurzfristige Komplikationen (z. B. eine Hypoglykämie) strikt zu vermeiden. Die Diabetestherapie sollte primär die persönli-chen Lebensziele des Patienten im Fokus haben, seine Lebensqualität sowie den Erhalt der funktionellen Unabhängigkeit.

• Literatur

• 1 Jacobs E, Hoyer A, Brinks R. et al. Burden of mortality attributable to diagnosed diabetes: a nationwide analysis based on claims data from 65 million people in Germany. Diabetes Care 2017; 40: 1703-1709 doi:10.2337/dc17-0954
• 2 Danesh J. for The Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA 2015; 314: 52-60 doi:10.1001/jama.2015.7008
• 3 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322 doi:10.1056/NEJMoa1603827
• 4 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Putcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2016; 373: 2117-2128 doi:10.1056/NEJMoa1504720
• 5 Fitchett D, Zinman B, Wanner C. et al. Heart failure outcomes with empagliflozin in patienets with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial investigators. Eur Heart J 2016; 37: 1526-1534 doi:10.1093/eurheartj/ehv728
• 6 Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in highrisk patients with diabetes mellitus. Eur Heart J 2016; 37: 3192-3200 doi:10.1093/eurheartj/ehw110
• 7 McMurray JJV, Gerstein HC, Holman RR. et al. Heart failure: a cardiovascular outcome in diabetes hat can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2: 843-851 doi: 10.1016/S2213-8587(14)70031-2
• 8 Bertoni AG, Hundley WG, Massing MW. et al. Heart Failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703 doi:10.2337/ diacare.27.3.699
• 9 Piepoli MF, Hoes AW, Agewall S. et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315-2381 doi:10.1093/eurheartj/ ehw106
• 10 Lytwin Y, Bjornstad P, Udell PA. et al. Sodium Glucose Transporter-2 Inhibition in Heart Failure. Circulation 2017; 136: 1643-1658 doi:10.1161/CIRCULATIONAHA.117.030012
• 11 Hoogeven EK, Geleijnse JM, Giltay EJ. et al. Kidney function and specific mortality in 60-80 vears old post-myocardial infarction patients: A 10-year follow-up study. PloS ONE 2017; 12: e0171868 doi:10.1371/journal.pone.0171868
• 12 Wu B, Bell K, Stanford A. et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care 2016; 4: e000154 doi:10.1136/bmjdrc-2015-000154
• 13 Wanner C, Inzucchi SE, Lachin JM. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334 doi: 10.1056/NEJMoa1515920
• 14 Quartuccio M, Buta B, Kalyani RR. Comparative effectiveness for glycemic control in older adults with diabetes. Curr Geri Rep 2017 6: 175-186 doi: 10.1007/s13670-017-0215-z
• 15 Farrell B, Black C, Thompson W. et al. Deprescribing antihypergylcemic agents in older persons. Evidence-based clinical practice guideline. Can Fam Physician 2017; 63: 832-843
• 16 Ellis G, Whitehead MA, Robinson D. et al. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ 2011; 343: d6553 doi:10.1136/bmj.d6553
• 17 American Diabetes Association. 6. Glycemic Targets. Diabetes Care 2017; 40 Suppl (Suppl. 01) S48-S56 doi:10.2337/ dc17-S009
• 18 Bremer JP, Jauch-Chara K, Hallschmid M. et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32: 1513-1517 doi: 10.2337/dc09-0114
• 19 Lipska KJ, Ross JS, Miao Y. et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015; 175: 356-362 doi: 10.1001/ jamainternmed.2014.7345
• 20 Huang ES, Laitererapong N, Liu JY. et al. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 2014; 174: 251-258 doi:10.1001/jamainternmed.2013.12956